Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions
Charlotte S. Walmsley, Adela Rodriguez, Panagiotis A. Konstantinopoulos, Geoffrey I. Shapiro, Sara M. Tolaney, Judy E. Garber, Filipa Lynce · 2026
Read Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions by Charlotte S. Walmsley, Adela Rodriguez, Panagiotis A. Konstantinopoulos, Geoffrey I. Shapiro, Sara M. Tolaney, Judy E. Garber, Filipa Lynce (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13626854.txt.
Description
Charlotte S Walmsley and co-authors review how PARP inhibitors, a class of cancer drugs, might reach more breast cancer patients. The drugs exploit broken DNA repair: about one tumor in ten cannot run homologous recombination, the high-fidelity repair path, and blocking the backup PARP system kills such cells. Approvals today cover early and advanced breast cancer in patients who inherit BRCA1 or BRCA2 mutations, the classic repair failure.
Fresh evidence hints the same trick works in tumors with other repair defects, a BRCA-like state called BRCAness, even without inherited mutations. The review weighs better biomarkers to find those tumors, drug combinations to deepen responses, and next-generation agents built to be choosier. Widening the net without diluting benefit is the field's central puzzle.
Catalog record
| CREATOR | Charlotte S. Walmsley, Adela Rodriguez, Panagiotis A. Konstantinopoulos, Geoffrey I. Shapiro, Sara M. Tolaney, Judy E. Garber, Filipa Lynce |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |